Literature DB >> 21187084

Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways.

Jinsheng Gao1, Hong Zhou, Tianluo Lei, Li Zhou, Weidong Li, Xuejun Li, Baoxue Yang.   

Abstract

Autosomal dominant polycystic kidney disease, a common inherited disease affecting about 1/1000 and 1/400 live births, is characterized by massive enlargement of fluid-filled cysts and eventually causes renal failure. The purpose of this study is to identify the inhibitory effect of curcumin on renal cyst development and to investigate the inhibitory mechanism. Madin-Darby canine kidney (MDCK) cyst model and murine embryonic kidney cyst model were used to evaluate inhibitory activity. Cell viability, proliferation, apoptosis, CFTR function and expression, and signaling pathways in MDCK cells were determined to explore the mechanism of cyst inhibition. Curcumin was found to significantly inhibit MDCK cyst development. At maximum dose curcumin caused 62% inhibition of the cyst formation (IC(50) was 0.12 μM). Curcumin slowed cyst enlargement in both MDCK cyst model and embryonic kidney cyst model with dose-response relationship. Curcumin neither induced cytotoxicity nor apoptosis in MDCK cells at <100 μM. Curcumin failed to affect the chloride transporter CFTR expression and function. Interestingly, curcumin inhibited forskolin-promoted cell proliferation and promoted the tubule formation in MDCK cells, which indicates curcumin promotes MDCK cell differentiation. Furthermore, curcumin reduced the intracellular signaling proteins Ras, B-raf, p-MEK, p-ERK, c-fos, Egr-1, but increased Raf-1 and NAB2 in MDCK cells exposed to forskolin. These results define that curcumin inhibits renal cyst formation and enlargement and suggest that curcumin might be developed as a candidate drug for polycystic kidney disease.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21187084     DOI: 10.1016/j.ejphar.2010.12.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

1.  An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2.

Authors:  Kameswaran Ravichandran; Iram Zafar; Zhibin He; R Brian Doctor; Radu Moldovan; Adam E Mullick; Charles L Edelstein
Journal:  Hum Mol Genet       Date:  2014-05-08       Impact factor: 6.150

Review 2.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Vicente E Torres
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 3.  Drug discovery for polycystic kidney disease.

Authors:  Ying Sun; Hong Zhou; Bao-xue Yang
Journal:  Acta Pharmacol Sin       Date:  2011-06       Impact factor: 6.150

Review 4.  New treatments for autosomal dominant polycystic kidney disease.

Authors:  Ming-Yang Chang; Albert C M Ong
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

5.  Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models.

Authors:  Hong Zhou; Jinsheng Gao; Li Zhou; Xin Li; Weidong Li; Xuejun Li; Yin Xia; Baoxue Yang
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-15

6.  STAT3 Signaling in Polycystic Kidney Disease.

Authors:  Thomas Weimbs; Jeffrey J Talbot
Journal:  Drug Discov Today Dis Mech       Date:  2013-12-01

7.  Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Authors:  Asmin Andries; Kristien Daenen; François Jouret; Bert Bammens; Djalila Mekahli; Ann Van Schepdael
Journal:  Pediatr Nephrol       Date:  2018-08-13       Impact factor: 3.714

8.  Polycystin-1 regulates amphiregulin expression through CREB and AP1 signalling: implications in ADPKD cell proliferation.

Authors:  Gianluca Aguiari; Fabiana Bizzarri; Anna Bonon; Alessandra Mangolini; Eros Magri; Massimo Pedriali; Patrizia Querzoli; Stefan Somlo; Peter C Harris; Luigi Catizone; Laura Del Senno
Journal:  J Mol Med (Berl)       Date:  2012-05-09       Impact factor: 4.599

Review 9.  Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2013-02

Review 10.  Applications of Herbal Medicine to Treat Autosomal Dominant Polycystic Kidney Disease.

Authors:  Guangying Shao; Shuai Zhu; Baoxue Yang
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.